Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Apr;19(4):513–518. doi: 10.1128/aac.19.4.513

Trimethoprim-rifampin, a new combination agent: efficacy in localized urinary infection and influence on microflora.

A M Bourgault, K R Forward, A R Ronald, G K Harding, M Thomson, G Grey
PMCID: PMC181468  PMID: 7247374

Abstract

Twenty women with recurrent or persistent urinary tract infections were treated with a fixed combination of trimethoprim-rifampin (TMP-RAM). The site of infection was established by the antibody-coated bacteria test. Sixteen women had upper tract infections (antibody-coated bacteria tests positive); eight were cured, three failed, and five relapsed. All four women with lower tract infections (antibody-coated bacteria tests negative) were cured. Three of five patients with structural abnormalities failed. The 12 cures and 5 relapses were associated with organisms susceptible to either TMP (minimal inhibitory concentration, less than or = to 7 micrograms/ml) or RAM (minimal inhibitory concentration, less than or = to 32 micrograms/ml). In contrast, two of the three failures were associated with organisms resistant to both TMP and RAM. In one patient, RAM resistance emerged during treatment. During therapy, urinary strains were eradicated from the periurethral and anal-canal areas in all but 3 fo 16 patients. Adverse reactions, noted in 16 women, included nausea (10), dizziness (6), headaches (2), rash (1), an blurred vision (1). Antimicrobial susceptibility data on 246 isolated from urinary, periurethral, and anal-canal specimens are included. Our findings suggest that TMP-RAM is effective in urinary infections and may prevent the emergence of RAM-resistant strains.

Full text

PDF
513

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Scotti R. Kinetic studies on the combination rifampicin-trimethoprim in man. I. Absorption and urinary excretion after administration to healthy volunteers of single doses of the two compounds alone and in combination, and of the combination over a period of 1 week. J Antimicrob Chemother. 1976 Sep;2(3):271–277. doi: 10.1093/jac/2.3.271. [DOI] [PubMed] [Google Scholar]
  2. Adachi T., de Almeida T. R. Controlled clinical trial of a rifampicin- trimethoprim combination (Rifaprim) and cotrimoxazole in patients with chronic urinary tract infections. J Int Med Res. 1979;7(2):132–137. doi: 10.1177/030006057900700204. [DOI] [PubMed] [Google Scholar]
  3. Arioli V., Berti M., Carniti G., Rossi E. Interaction between rifampicin and trimethoprim in vitro and in experimental infections. J Antimicrob Chemother. 1977 Jan;3(1):87–94. doi: 10.1093/jac/3.1.87. [DOI] [PubMed] [Google Scholar]
  4. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  5. Buckwold F. J., Ronald A. R., Harding G. K., Marrie T. J., Fox L., Cates C. Biotyping of Escherichia coli by a simple multiple-inoculation agar plate technique. J Clin Microbiol. 1979 Sep;10(3):275–278. doi: 10.1128/jcm.10.3.275-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farrell W., Wilks M., Drasar F. A. The action of trimethoprim and rifampicin in combination against Gram-negative rods resistant to gentamicin. J Antimicrob Chemother. 1977 Sep;3(5):459–462. doi: 10.1093/jac/3.5.459. [DOI] [PubMed] [Google Scholar]
  7. Goldstein B. P., Ripamonti I. F., Bolzoni G., Carniti G., Arioli V. Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro. Antimicrob Agents Chemother. 1979 Dec;16(6):736–742. doi: 10.1128/aac.16.6.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grüneberg R. N., Emmerson A. M. The interactions between rifampicin and trimethoprim: an in vitro study. J Antimicrob Chemother. 1977 Sep;3(5):453–457. doi: 10.1093/jac/3.5.453. [DOI] [PubMed] [Google Scholar]
  9. Harding G. K., Marrie T. J., Ronald A. R., Hoban S., Muir P. Urinary tract infection localization in women. JAMA. 1978 Sep 8;240(11):1147–1151. [PubMed] [Google Scholar]
  10. Kerry D. W., Hamilton-Miller J. M., Brumfitt W. Trimethoprim and rifampicin: in vitro activities separately and in combination. J Antimicrob Chemother. 1975 Dec;1(4):417–427. doi: 10.1093/jac/1.4.417. [DOI] [PubMed] [Google Scholar]
  11. McCabe W. R., Lorian V. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am J Med Sci. 1968 Oct;256(4):255–265. doi: 10.1097/00000441-196810000-00007. [DOI] [PubMed] [Google Scholar]
  12. Palminteri R., Sassella D. Double-blind multicenter trial of a rifampicin-trimethoprim combination and rifampicin alone in urinary tract infections. Chemotherapy. 1979;25(3):181–188. doi: 10.1159/000237838. [DOI] [PubMed] [Google Scholar]
  13. Ronald A. R., Jagdis F. A., Harding G. K., Hoban S. A., Miur P. L., Gurwith M. J. Amoxicillin therapy of acute urinary infections in adults. Antimicrob Agents Chemother. 1977 May;11(5):780–784. doi: 10.1128/aac.11.5.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thomas V., Shelokov A., Forland M. Antibody-coated bacteria in the urine and the site of urinary-tract infection. N Engl J Med. 1974 Mar 14;290(11):588–590. doi: 10.1056/NEJM197403142901102. [DOI] [PubMed] [Google Scholar]
  15. Winberg J., Bergström T., Lincoln K., Lidin-Janson G. Treatment trials in urinary tract infection (UTI) with special reference to the effect of antimicrobials on the fecal and periurethral flora. Clin Nephrol. 1973 May-Jun;1(3):142–148. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES